Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit.

Abuannadi M, Kosiborod M, Riggs L, House JA, Hamburg MS, Kennedy KF, Marso SP

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists1 Jan 2013Cited by 38 (Europe PMC)

PMID23186969DOI10.4158/ep12196.orPepBankPUB-23186969

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In cardiac intensive care patients, exenatide was discontinued in 3 patients because glycemic control failed.
In plain wordsIn cardiac intensive care patients, 3 stopped exenatide because it did not control blood sugar.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableDiscontinuation for inadequate control
Study
n = 40
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenous · Up to 48 hoursAs given in this study (human).
Measurements
Patients discontinued for failed glycemic control
3 patients
exenatide group
Source sentences
Summary
Exenatide was discontinued in 3 patients after failure to achieve glycemic control.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, single-center, open-label, nonrandomized pilot study.
Summary · context
Forty patients admitted to the CICU with glucose levels of 140 to 400 mg/dL received intravenous exenatide as a bolus followed by a fixed dose infusion for up to 48 hours.
Summary · context
Exenatide effectiveness was benchmarked to two historical insulin infusion cohorts, one (INT) with a target glucose of 90 to 119 mg/dL (n = 84) and the other (MOD) with a target of 100 to 140 mg/dL (n = 71).
Report a problemFND-2318696905
02HumanNon-randomized trialSafety outcome
In cardiac intensive care patients receiving exenatide, no severe hypoglycemia episodes occurred.
In plain wordsIn cardiac intensive care patients receiving exenatide, no severe low blood sugar episodes occurred.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableSevere hypoglycemia
Study
n = 40
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · intravenous · Up to 48 hoursAs given in this study (human).
Source sentences
Summary
No episodes of severe hypoglycemia (<50 mg/dL) occurred in patients who received exenatide.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, single-center, open-label, nonrandomized pilot study.
Summary · context
Forty patients admitted to the CICU with glucose levels of 140 to 400 mg/dL received intravenous exenatide as a bolus followed by a fixed dose infusion for up to 48 hours.
Summary · context
Exenatide effectiveness was benchmarked to two historical insulin infusion cohorts, one (INT) with a target glucose of 90 to 119 mg/dL (n = 84) and the other (MOD) with a target of 100 to 140 mg/dL (n = 71).
Report a problemFND-2318696906
03HumanNon-randomized trialSafety outcome
In cardiac intensive care patients receiving exenatide, 16 reported nausea.
In plain wordsIn cardiac intensive care patients receiving exenatide, 16 reported nausea.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableNausea
Study
n = 40
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · intravenous · Up to 48 hoursAs given in this study (human).
Measurements
Patients with nausea
16 patients
exenatide
Source sentences
Summary
Nausea was reported by 16 patients and vomiting by 2 patients.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, single-center, open-label, nonrandomized pilot study.
Summary · context
Forty patients admitted to the CICU with glucose levels of 140 to 400 mg/dL received intravenous exenatide as a bolus followed by a fixed dose infusion for up to 48 hours.
Summary · context
Exenatide effectiveness was benchmarked to two historical insulin infusion cohorts, one (INT) with a target glucose of 90 to 119 mg/dL (n = 84) and the other (MOD) with a target of 100 to 140 mg/dL (n = 71).
Report a problemFND-2318696907
04HumanNon-randomized trialSafety outcome
In cardiac intensive care patients receiving exenatide, 2 reported vomiting.
In plain wordsIn cardiac intensive care patients receiving exenatide, 2 reported vomiting.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableVomiting
Study
n = 40
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · intravenous · Up to 48 hoursAs given in this study (human).
Measurements
Patients with vomiting
2 patients
exenatide
Source sentences
Summary
Nausea was reported by 16 patients and vomiting by 2 patients.
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, single-center, open-label, nonrandomized pilot study.
Summary · context
Forty patients admitted to the CICU with glucose levels of 140 to 400 mg/dL received intravenous exenatide as a bolus followed by a fixed dose infusion for up to 48 hours.
Summary · context
Exenatide effectiveness was benchmarked to two historical insulin infusion cohorts, one (INT) with a target glucose of 90 to 119 mg/dL (n = 84) and the other (MOD) with a target of 100 to 140 mg/dL (n = 71).
Report a problemFND-2318696908
05HumanNon-randomized trialEfficacy outcome
In cardiac intensive care patients, steady-state glucose was similar with exenatide and MOD insulin infusion.
In plain wordsIn cardiac intensive care patients, steady blood sugar was similar with exenatide and MOD insulin infusion.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSteady-state glucose versus MOD
Study
n: not reported in source
Comparator
Historical MOD insulin infusion cohort
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenous · Up to 48 hoursAs given in this study (human).
Measurements
Median steady-state glucose
132 mg/dL
exenatide
Median steady-state glucose
127 mg/dL
MOD historical insulin cohort
Source sentences
Summary
Steady state glucose values were similar between the exenatide (132.0 mg/dL [110.0, 157.0]) and the MOD groups (127.0 mg/dL [105.0, 161.0], P = .15), but lower in the INT group (105.0 mg/dL [92.0, 128.0], P<.001 for exenatide versus INT).
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, single-center, open-label, nonrandomized pilot study.
Summary · context
Forty patients admitted to the CICU with glucose levels of 140 to 400 mg/dL received intravenous exenatide as a bolus followed by a fixed dose infusion for up to 48 hours.
Summary · context
Exenatide effectiveness was benchmarked to two historical insulin infusion cohorts, one (INT) with a target glucose of 90 to 119 mg/dL (n = 84) and the other (MOD) with a target of 100 to 140 mg/dL (n = 71).
Report a problemFND-2318696901
06HumanNon-randomized trialEfficacy outcome
In cardiac intensive care patients, steady-state glucose was higher with exenatide than INT insulin infusion.
In plain wordsIn cardiac intensive care patients, steady blood sugar was higher with exenatide than INT insulin infusion.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSteady-state glucose versus INT
Study
n: not reported in source
Comparator
Historical INT insulin infusion cohort
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenous · Up to 48 hoursAs given in this study (human).
Measurements
Median steady-state glucose
132 mg/dL
exenatide
Median steady-state glucose
105 mg/dL
INT historical insulin cohort
Source sentences
Summary
Steady state glucose values were similar between the exenatide (132.0 mg/dL [110.0, 157.0]) and the MOD groups (127.0 mg/dL [105.0, 161.0], P = .15), but lower in the INT group (105.0 mg/dL [92.0, 128.0], P<.001 for exenatide versus INT).
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, single-center, open-label, nonrandomized pilot study.
Summary · context
Forty patients admitted to the CICU with glucose levels of 140 to 400 mg/dL received intravenous exenatide as a bolus followed by a fixed dose infusion for up to 48 hours.
Summary · context
Exenatide effectiveness was benchmarked to two historical insulin infusion cohorts, one (INT) with a target glucose of 90 to 119 mg/dL (n = 84) and the other (MOD) with a target of 100 to 140 mg/dL (n = 71).
Report a problemFND-2318696902
07HumanNon-randomized trialEfficacy outcome
In cardiac intensive care patients, exenatide reached steady-state glucose faster than MOD insulin infusion.
In plain wordsIn cardiac intensive care patients, blood sugar stabilized faster with exenatide than MOD insulin infusion.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseTime to steady state versus MOD
Study
n: not reported in source
Comparator
Historical MOD insulin infusion cohort
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenous · Up to 48 hoursAs given in this study (human).
Measurements
Median time to steady state
2 hours
exenatide
Median time to steady state
12 hours
MOD historical insulin cohort
Source sentences
Summary
Median (IQR) time to steady state was 2.0 hours (1.5, 5.0) in the exenatide group compared to 12.0 hours (7.0, 15.0) in the MOD group (P<.001) and 3.0 hours (1.0, 5.0) in the INT group (P = .80 for exenatide versus INT).
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, single-center, open-label, nonrandomized pilot study.
Summary · context
Forty patients admitted to the CICU with glucose levels of 140 to 400 mg/dL received intravenous exenatide as a bolus followed by a fixed dose infusion for up to 48 hours.
Summary · context
Exenatide effectiveness was benchmarked to two historical insulin infusion cohorts, one (INT) with a target glucose of 90 to 119 mg/dL (n = 84) and the other (MOD) with a target of 100 to 140 mg/dL (n = 71).
Report a problemFND-2318696903
08HumanNon-randomized trialEfficacy outcome
In cardiac intensive care patients, time to steady-state glucose did not differ significantly between exenatide and INT insulin infusion.
In plain wordsIn cardiac intensive care patients, blood sugar stabilization time was similar with exenatide and INT insulin infusion.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeTime to steady state versus INT
Study
n: not reported in source
Comparator
Historical INT insulin infusion cohort
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · intravenous · Up to 48 hoursAs given in this study (human).
Measurements
Median time to steady state
2 hours
exenatide
Median time to steady state
3 hours
INT historical insulin cohort
Source sentences
Summary
Median (IQR) time to steady state was 2.0 hours (1.5, 5.0) in the exenatide group compared to 12.0 hours (7.0, 15.0) in the MOD group (P<.001) and 3.0 hours (1.0, 5.0) in the INT group (P = .80 for exenatide versus INT).
3 context sentences(design, population, supporting numbers)
Summary · context
A prospective, single-center, open-label, nonrandomized pilot study.
Summary · context
Forty patients admitted to the CICU with glucose levels of 140 to 400 mg/dL received intravenous exenatide as a bolus followed by a fixed dose infusion for up to 48 hours.
Summary · context
Exenatide effectiveness was benchmarked to two historical insulin infusion cohorts, one (INT) with a target glucose of 90 to 119 mg/dL (n = 84) and the other (MOD) with a target of 100 to 140 mg/dL (n = 71).
Report a problemFND-2318696904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT00736229

Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

Saint Luke's Health Systemn = 40Aug 2008 to Aug 2012

Hyperglycemia · Acute Coronary Syndromes · Myocardial Infarction

Trial page ClinicalTrials.govUpdated 20 Nov 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.